Valuation : Recursion Pharmaceuticals, Inc.

Market Cap 1.84B 1.59B 1.49B 1.36B 2.54B 175B 2.55B 17.68B 6.84B 89.39B 6.93B 6.78B 284B P/E 2026 *
-3.92x
P/E 2027 * -4x
Enterprise Value 1.46B 1.25B 1.18B 1.08B 2.01B 138B 2.02B 13.97B 5.4B 70.61B 5.47B 5.35B 225B EV / Sales 2026 *
34.1x
EV / Sales 2027 * 28.8x
Free-Float
97.73%
Yield 2026 *
-
Yield 2027 * -
1 day-5.23%
1 week+3.30%
Current month+1.18%
1 month+6.83%
3 months+3.61%
6 months-0.58%
Current year-15.89%
1 week 3.29
Extreme 3.2901
3.7
1 month 2.92
Extreme 2.92
3.7
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
29.36
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Sell

Founder

-30,000 0.0056%
8/17/26 Tax

Chief Technology Officer

-26,657 0.0051%
8/17/26 Tax

Chief Executive Officer

-80,498 0.0153%
Change 5-day change 1-year change 3-year change Capi.($)
-5.23%+3.30%-25.54%-57.32% 1.84B
+2.02%+1.26%+41.37%+105.18% 69.19B
-0.92%-4.73%+31.43%+74.50% 62.97B
-1.11%+2.78%-14.86%+375.59% 27.27B
-4.92%-3.22%-3.90%-17.87% 24.78B
-1.26%-1.06%+29.37%+14.10% 25.8B
+0.25%-0.18%+23.42%-16.24% 20.11B
+6.04%+7.25%+233.25%+383.12% 18.47B
-1.52%-2.31%-8.00%+516.65% 14.88B
-2.27%+1.37%+53.01%+160.83% 14.29B
Average -0.85%+0.99%+35.96%+153.85% 27.96B
Weighted average by Cap. -0.15%+0.13%+37.44%+138.63%

Financials

2026 *2027 *
Net sales 42.68M 36.7M 34.53M 31.51M 58.8M 4.05B 59.1M 409M 158M 2.07B 160M 157M 6.58B 56.25M 48.36M 45.5M 41.52M 77.49M 5.33B 77.89M 539M 209M 2.73B 211M 207M 8.67B
Net income -459M -394M -371M -339M -632M -43.49B -635M -4.4B -1.7B -22.23B -1.72B -1.69B -70.74B -474M -408M -384M -350M -653M -44.97B -657M -4.55B -1.76B -22.99B -1.78B -1.74B -73.15B
Net Debt -388M -333M -313M -286M -534M -36.74B -537M -3.71B -1.44B -18.78B -1.46B -1.42B -59.75B -227M -195M -183M -167M -312M -21.49B -314M -2.17B -841M -10.98B -851M -833M -34.95B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-09-08 US$3.440 -5.23% 14,990,246
26-09-04 US$3.630 +5.52% 29,039,059
26-09-03 US$3.440 +1.78% 13,746,067
26-09-02 US$3.380 +1.50% 14,052,683
26-09-01 US$3.330 -2.06% 9,996,546
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.440USD
Average target price
7.217USD
Spread / Average Target
+109.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!